Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 8/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21358424 | 0.93 | ENPP1 (0.71) | ENPP1MAPK1ACHEBACE1HTR1A | |
| SCHEMBL29354481 | 0.93 | ENPP1 (0.71) | ENPP1MAPK1ACHEBACE1HTR1A | |
| SCHEMBL23727319 | 0.90 | ENPP1 (0.73) | ENPP1MAPK1ACHEBACE1HTR1A | |
| SCHEMBL22407607 | 0.87 | ENPP1 (0.62) | ENPP1MAPK1ACHEBACE1HTR1A | |
| SCHEMBL22407359 | 0.87 | ENPP1 (0.62) | ENPP1MAPK1ACHEBACE1HTR1A | |
| SCHEMBL22407453 | 0.86 | ENPP1 (0.61) | ENPP1MAPK1PDGFRBACHEBACE1 | |
| SCHEMBL22407443 | 0.86 | ENPP1 (0.61) | ENPP1MAPK1PDGFRBACHEBACE1 | |
| SCHEMBL20782509 | 0.85 | ENPP1 (0.88) | ENPP1 | |
| SCHEMBL22407331 | 0.83 | ENPP1 (0.66) | ENPP1MAPK1PDGFRBACHEBACE1 | |
| SCHEMBL29355270 | 0.83 | ENPP1 (0.60) | ENPP1MAPK1PDGFRBACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ENPP1 1/4885MAPK1 2004/4885PDGFRB 488/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ENPP1 1/4885MAPK1 2004/4885PDGFRB 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.